Physician profile
Winnie Chen
NPI 1225603061
$5,570.30
in general payments reported to CMS, 2019-2025
33 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $601 · 2023: $1,522 · 2024: $1,574 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,721 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,721.26 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $895.51 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $874.80 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $662.82 | 2023-2025 | Veozah |
| Novo Nordisk INC | $599.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $404.07 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $350.11 | 2022-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $345.49 | 2022-2025 | |
| Pfizer INC. | $237.60 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.27 | 2022-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $116.71 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $97.91 | 2025 | |
| Exact Sciences Corporation | $91.86 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $76.54 | 2022-2023 | |
| Dexcom, INC. | $68.18 | 2023-2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $61.78 | 2023-2025 | Heplisav-B |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.39 | 2024-2025 | Jardiance, Jascayd |
| Boston Scientific Corporation | $51.36 | 2023-2025 | Watchman Flx, Watchman Access System |
| Genentech USA, INC. | $49.96 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.09 | 2022-2024 | |
| Inari Medical, INC. | $42.07 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Acella Pharmaceuticals, LLC | $35.63 | 2024-2025 | NP Thyroid 60 |
| Paratek Pharmaceuticals, INC. | $33.91 | 2025 | Nuzyra, Xhance |
| Gilead Sciences, INC. | $28.50 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.10 | 2022 | |
| Ibsa Pharma INC. | $26.76 | 2022 | |
| Viiv Healthcare Company | $25.41 | 2024 | Apretude |
| Vbi Vaccine (Delaware) INC. | $25.33 | 2022 | |
| Corcept Therapeutics | $20.10 | 2025 | Korlym |
| Sanofi Pasteur INC. | $19.51 | 2025 | |
| Uswm, LLC | $17.15 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.32 | 2023 | Edarbi |
| Kowa Pharmaceuticals America, INC. | $12.49 | 2022 | |
| Orthofix Medical, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winnie Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.